A recent white paper recaps the many barriers to biosimilar adoption in the United States and proposes a few ways that plans could change their reimbursement policies to help boost uptake.
A recent white paper recaps the many barriers to biosimilar adoption in the United States and proposes a few ways that plans could change their reimbursement policies to help boost uptake.
The paper, by Millman, said that fixed reimbursement, a system in which providers would be reimbursed the same amount no matter which product was administered (reference product or biosimilar) would create an incentive to prescribe the lowest-price product.
Differential reimbursement, meanwhile, would allow a larger markup on biosimilars so that providers would be safeguarded from a loss in profits. Commercial payers would pay more in markup, but since they have a lower average sales price, it would be less expensive to pay for biosimilars with a higher markup than an originator product with a lower markup. This would lead to higher biosimilar reimbursement for commercial payers but overall savings if providers had a financial incentive to prescribe biosimilars.
Federal policy changes could also increase the use of biosimilars, the paper said. Specifically, it cited the following:
The paper also cited the FDA’s Biosimilar Action Plan, including the 4 key strategies to induce competition in the US market. They include increasing efficiency around the development and approval process; expanding the Purple Book in order to increase clarity and support around biosimilar development, as well as the Biosimilar Product Development program to speed up and promote development; an education initiative; and reducing attempts to delay approval by originator manufacturers of reference products.
The report notes that some of the most “meaningful solutions are largely beyond the authority of the FDA.”
In fact, this week HHS issued a proposed rule that could help the market for biosimilars. The rule is intended to reduce patients’ out-of-pocket costs for prescription drugs by blocking rebates and discounts given to pharmacy benefit managers (PBMs), Part D plans, and Medicaid managed care organizations and encourage discounts to go straight to patients.
The rule would exclude rebates from safe harbor protections that currently shelter drug makers’ rebates from penalties under the federal anti-kickback statute, and would create new safe harbor for discounts offered to patients, as well as fixed-fee service arrangements between drug makers and PBMs.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.